Sukumar Nagendran, President and Head of R&D at Taysha Gene Therapies, Inc. (TSHA), sold 200,000 shares at $4.71 ($942K) on 2026-01-12, disclosed to the SEC on 2026-01-14.
Open-market sale of $942k TSHA by President and Head of R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| TSHA | SELL | 2026-01-27 | $547K | — | Filing → |
| TSHA | SELL | 2025-12-01 | $3.4M | — | Filing → |
| TSHA | SELL | 2025-09-12 | $646K | — | Filing → |